US big pharma company Pfizer has approached its UK rival AstraZeneca with a £60bn takeover offer, reports The Sunday Times (20 April). AstraZeneca allegedly rebuffed the advance and talks have been discontinued. If such an offer was indeed made, it would equate to roughly £48 per AstraZeneca share, a premium of more than 25% above its last close.
The paper cites unnamed senior investment bankers and industry sources, although the actual timing of the discussions remain rather vague....


![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

